ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - OncoDaily Rowan Study with Durvalumab and Tremelimumab and Therasphere in HCC completed enrollment

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ROWAN #TheraSphere #Durvalumab #Tremelimumab #HCC